Manufacturing

Starpharma licenses VivaGel BV to Mundipharma for Europe

Starpharma and Mundipharma have signed a licence agreement for the sales and marketing rights to VivaGel BV for 43 countries in Europe, Russia, the Commonwealth of Independent States (CIS) and the balance of countries in Latin America.

Takeda to sell Techpool to Chinese JV partners

Takeda Pharmaceutical has agreed to divest its its majority shareholding of 51.34% in Guangdong Techpool Bio-Pharma (Techpool), a China-based firm focused on urinary protein biopharmaceuticals and production of biopharmaceuticals in critical care, to its joint venture (JV) partners for $280m.

Amryt, Aegerion sign expanded deal for Lojuxta capsules

Amryt has signed an agreement with Aegerion Pharmaceuticals to expand its exclusive licence agreement for Lojuxta (lomitapide) into Russia and the Commonwealth of Independent States (CIS), as well as the non-EU Balkan states.

Takeda agrees to acquire Shire for £45.3bn

Takeda Pharmaceutical has agreed to acquire Ireland-based rare disease biotech company Shire in a cash-cum stock deal worth around £45.3bn.

Endo to buy Somerset Therapeutics for $190m

Endo International has agreed to acquire New Jersey-based Somerset Therapeutics, that develops and markets sterile injectable and ophthalmic drugs, and the business of its India-based affiliate Wintac, which operates as Somerset's contract developer and manufacturer.

Shire considers Takeda’s revised £46bn takeover offer

Shire’s board said that it is willing to recommend Takeda Pharmaceutical’s revised acquisition offer of £46bn to its shareholders.

Synpromics to partner with Lonza to improve biopharmaceuticals manufacturing

Synpromics has partnered with Lonza Pharma & Biotech to further develop its inducible promoter system and enhance manufacturing of biopharmaceuticals.

Fresenius Kabi scraps $4.3bn merger with US generic drugmaker Akorn

Germany-based Fresenius Kabi has scrapped its $4.3bn merger agreement with Akorn, saying that the US generic drugmaker did not fulfill various closing conditions.

Merck to sell global consumer health business to P&G for $4.2bn

Merck has agreed to sell its global consumer health business to Procter & Gamble (P&G) for about €3.4bn ($4.2bn).